Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
G protein-coupled receptors not currently in the spotlight: free fatty acid receptor 2 and GPR35 [PDF]
, 2017 It is widely appreciated that G protein-coupled receptors have been the most successfully exploited class of targets for the development of small molecule medicines. Despite this, to date, less than 15% of the non-olfactory G protein-coupled receptors in
Milligan, Graeme
core +1 more source
GLP-1 receptor agonists for Parkinson's disease
Cochrane Database of Systematic Reviews, 2020 Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain.
Caroline A, Mulvaney +6 more
openaire +3 more sources
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Frontiers in Neuroscience, 2022 Glaucoma is a common ocular neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and their axons. It is the most common cause of irreversible blindness.
Zaynab Ahmad Mouhammad +11 more
doaj +1 more source
Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi +64 more
core +6 more sources
The effects of species ortholog and SNP variation on receptors for free fatty acids [PDF]
, 2013 Although it is widely assumed that species orthologs of hormone responsive G protein-coupled receptors will be activated by the same endogenously produced ligand(s), variation in potency, particularly in cases where more than one receptor responds to the
1000 Genomes Project Consortium +72 more
core +1 more source
Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]
, 2010 Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Clar, C. +4 more
core +5 more sources
Adverse Effects of GLP-1 Receptor Agonists [PDF]
The Review of Diabetic Studies, 2014 Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D). However, the use of this relatively new class of drugs may be associated with certain adverse effects.
Theodosios D, Filippatos +2 more
openaire +2 more sources
GLP-1 receptor agonists and the risk of thyroid cancer
Diabetes Care, 2022 <p> </p> <p><em>Objective</em></p> <p>To determine whether the use of GLP-1 receptor agonists (RA) is associated with an increased risk of thyroid cancer.</p> <p><em>Research Design and Methods</em></p> <p>A nested case-control analysis was performed using the French ...
Bezin, Julien +7 more
openaire +3 more sources
What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]
, 2019 Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra +13 more
core +1 more source